Patients with metastatic melanoma who undergo surgery to remove lesions that have spread into the abdomen live more than twice as long as those treated with drug therapy alone, according to novel new research by a North Shore-LIJ ...
Oct 8, 2015
0
17
Today, the US Food and Drug Administration (FDA) approved the immunotherapy combination nivolumab (Opdivo) plus ipilimumab (Yervoy) for use in patients with metastatic melanoma. This is the first-ever combination immunotherapy ...
Oct 5, 2015
0
15
A simple blood test can detect early markers of "reinvigorated" T cells and track immune responses in metastatic melanoma patients after initial treatment with the anti-PD-1 drug pembrolizumab, researchers from the Abramson ...
Sep 16, 2015
0
34
Within the past few years, new treatments have begun to turn the tide against metastatic melanoma, improving and even saving the lives of countless people with this deadly disease.
Sep 11, 2015
0
16
(HealthDay)—For patients with metastatic melanoma treated with mitogen-activated protein kinase (MAPK) inhibitors, gender, serum lactate dehydrogenase (LDH), BRAF genotype, and primary melanoma ulceration status are independent ...
Aug 3, 2015
0
14
In the spring of 2012, Tom Stutz was a man without a future. Just getting through the day took all of his energy and determination.
Jun 29, 2015
0
175
Mayo Clinic and the Translational Genomics Research Institute (TGen) are helping launch a national clinical trial that will apply the latest in precision medicine to treat advanced melanoma skin cancer.
Jun 22, 2015
0
6
Results of two clinical trials reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show continued promise of immune therapies nivolumab and pembrolizumab against advanced melanomas, specifically ...
Jun 1, 2015
0
8
Melanoma is predicted to result in approximately 10,000 deaths in 2015. The majority of these deaths are due to advanced stage disease that has spread or metastasized to other sites. The prognosis for patients with metastatic ...
May 20, 2015
0
31
Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 ...
Apr 20, 2015
0
10
